{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:52:19Z","timestamp":1780581139038,"version":"3.54.1"},"reference-count":13,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Cannabis Cannabinoids"],"abstract":"<jats:p>We present the case of a 12-year-old boy diagnosed with Tourette syndrome, who was successfully treated with a combination of vaporized medicinal cannabis and oral pure tetrahydrocannabinol (THC). Due to severe motor tics resulting in insomnia, the parents \u2013 both of whom were medical doctors \u2013 decided to initiate treatment with 0.02 g vaporized cannabis (Bedrocan with a THC content of 22% and a cannabidiol content of 1%; corresponding to a dose equivalent to 4.4 mg THC) without prior consultation of a Tourette expert. This treatment resulted \u2013 according to the parents\u2019 report \u2013 in an immediate and nearly complete remission of the tics. Due to a further increase in tics, the parents therefore decided to implement a regular treatment with a combination of vaporized medicinal cannabis (up to 0.1 g cannabis per day, varieties Bedrocan and Amnesia Haze, corresponding to 22 mg THC\/day) plus orally administered oil-based THC drops (maximum daily dose = 12.5 mg THC) resulting in a marked tic reduction. During a visit in our clinic, we were able to observe the reported beneficial effects 30 min after vaporization of 0.15 g cannabis (Amnesia Haze, equivalent to 33 mg THC; in addition, 7 mg oral THC were taken at home 6 h before the visit): tics, premonitory urges, and overall impairment significantly improved according to self-ratings, parent and clinician questionnaires. Importantly, no adverse events were reported. From this single case study, it is suggested that cannabis-based medicines and their combination (such as oral THC plus vaporized medicinal cannabis) are effective and safe in the treatment of severe tics in minors with TS. However, long-term follow-up is needed to confirm the beneficial treatment effects. We want to emphasize that in this boy treatment with cannabis was initiated by the parents before a consultation in our clinic has taken place. In our opinion, treatment with cannabis-based medicine in children should be regarded as a last-line treatment, when well-established treatments have failed to improve tics.<\/jats:p>","DOI":"10.1159\/000496355","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T22:01:17Z","timestamp":1548453677000},"page":"60-64","source":"Crossref","is-referenced-by-count":14,"title":["Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome"],"prefix":"10.1159","volume":"2","author":[{"given":"Natalia","family":"Szejko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgeni","family":"Jakubovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Fremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten\u00a0R.","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.16110310"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1039856216663737"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7050047"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d236ec"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.24911\/ejmcr\/2\/11"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.01.003"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1818"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1998.tb10127.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)00194-B"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-20.6.462"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2016.07.021"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.0335"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(14)00117-5"}],"container-title":["Medical Cannabis and Cannabinoids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/496355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/496355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:24:11Z","timestamp":1745429051000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000496355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,9,24]]},"published-print":{"date-parts":[[2019,9,17]]}},"URL":"https:\/\/doi.org\/10.1159\/000496355","archive":["Portico"],"relation":{},"ISSN":["2504-3889"],"issn-type":[{"value":"2504-3889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]}}}